Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer
BETHESDA, Md--The FDA has approved Burroughs Wellcome's Navelbine (vinorelbine tartrate) for the first-line treatment of ambulatory patients with unresectable, advanced non-small-cell lung cancer (NSCLC).
BETHESDA, Md--The FDA has approved Burroughs Wellcome's Navelbine(vinorelbine tartrate) for the first-line treatment of ambulatorypatients with unresectable, advanced non-small-cell lung cancer(NSCLC).
Navelbine, an intravenous therapy given on an outpatient basis,is the first new drug approved for NSCLC in 20 years. It is indicatedfor use as a single agent for treating patients with stage IVNSCLC and in combination with cisplatin (Platinol) for treatingstage III or IV disease. A fuller report on Navelbine's approvalwill appear in the February issue of ONI.
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
